## **R** Balfour Sartor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6138017/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	BET Protein Inhibition Regulates Macrophage Chromatin Accessibility and Microbiota-Dependent Colitis. Frontiers in Immunology, 2022, 13, 856966.	4.8	4
2	Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease. JCI Insight, 2022, 7, .	5.0	17
3	Dietary Fructose Alters the Composition, Localization, and Metabolism of Gut Microbiota in Association With Worsening Colitis. Cellular and Molecular Gastroenterology and Hepatology, 2021, 11, 525-550.	4.5	58
4	B-Cell Commitment to IL-10 Production: The VertX Il10egfp Mouse. Methods in Molecular Biology, 2021, 2270, 341-358.	0.9	2
5	â€ <sup>-</sup> Bugs on drugs': implications for gut health. Nature Reviews Gastroenterology and Hepatology, 2021, 18, 287-288.	17.8	Ο
6	Rationally designed bacterial consortia to treat chronic immune-mediated colitis and restore intestinal homeostasis. Nature Communications, 2021, 12, 3105.	12.8	82
7	RNF20 and RNF40 regulate vitamin D receptor-dependent signaling in inflammatory bowel disease. Cell Death and Differentiation, 2021, 28, 3161-3175.	11.2	10
8	Targeting Adaptive Immune Responses to Human Bacterial Flagellins in Crohn's Disease. Gastroenterology, 2021, 161, 416-418.	1.3	1
9	Reporting guidelines for human microbiome research: the STORMS checklist. Nature Medicine, 2021, 27, 1885-1892.	30.7	170
10	Neuroinflammation in Murine Cirrhosis Is Dependent on the Gut Microbiome and Is Attenuated by Fecal Transplant. Hepatology, 2020, 71, 611-626.	7.3	76
11	Multi-omics analyses of radiation survivors identify radioprotective microbes and metabolites. Science, 2020, 370, .	12.6	260
12	Crohn's Disease Differentially Affects Region-Specific Composition and Aerotolerance Profiles of Mucosally Adherent Bacteria. Inflammatory Bowel Diseases, 2020, 26, 1843-1855.	1.9	9
13	Targeted inhibition of gut bacterial β-glucuronidase activity enhances anticancer drug efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 7374-7381.	7.1	121
14	Strategies to Dissect Host-Microbial Immune Interactions That Determine Mucosal Homeostasis vs. Intestinal Inflammation in Gnotobiotic Mice. Frontiers in Immunology, 2020, 11, 214.	4.8	23
15	Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2020, 65, 757-788.	2.3	97
16	Growth effects of N-acylethanolamines on gut bacteria reflect altered bacterial abundances in inflammatory bowel disease. Nature Microbiology, 2020, 5, 486-497.	13.3	59
17	Phosphoinositide 3-Kinase P110δ-Signaling Is Critical for Microbiota-Activated IL-10 Production by B Cells that Regulate Intestinal Inflammation. Cells, 2019, 8, 1121.	4.1	15
18	Challenges in IBD Research: Precision Medicine. Inflammatory Bowel Diseases, 2019, 25, S31-S39.	1.9	67

#	Article	IF	CITATIONS
19	Influence of Crohn's disease related polymorphisms in innate immune function on ileal microbiome. PLoS ONE, 2019, 14, e0213108.	2.5	13
20	Yersiniabactin-Producing Adherent/Invasive Escherichia coli Promotes Inflammation-Associated Fibrosis in Gnotobiotic <i> Il10 <sup>â^'/â^'</sup> </i> Mice. Infection and Immunity, 2019, 87, .	2.2	38
21	Murine Adherent and Invasive <i>E. coli</i> Induces Chronic Inflammation and Immune Responses in the Small and Large Intestines of Monoassociated IL-10-/- Mice Independent of Long Polar Fimbriae Adhesin A. Inflammatory Bowel Diseases, 2019, 25, 875-885.	1.9	27
22	Predicting Risk of Postoperative Disease Recurrence in Crohn's Disease: Patients With Indolent Crohn's Disease Have Distinct Whole Transcriptome Profiles at the Time of First Surgery. Inflammatory Bowel Diseases, 2019, 25, 180-193.	1.9	18
23	A screen of Crohn's disease-associated microbial metabolites identifies ascorbate as a novel metabolic inhibitor of activated human T cells. Mucosal Immunology, 2019, 12, 457-467.	6.0	44
24	Microbiota maintain colonic homeostasis by activating TLR2/MyD88/PI3K signaling in IL-10–producing regulatory B cells. Journal of Clinical Investigation, 2019, 129, 3702-3716.	8.2	127
25	Environmental factors regulate Paneth cell phenotype and host susceptibility to intestinal inflammation in Irgm1-deficient mice. DMM Disease Models and Mechanisms, 2018, 11, .	2.4	22
26	Molecular classification of Crohn's disease reveals two clinically relevant subtypes. Gut, 2018, 67, 36-42.	12.1	89
27	Guiding longitudinal sampling in IBD cohorts. Gut, 2018, 67, 1743-1745.	12.1	32
28	Opioid Toxicity in Inflammatory Bowel Disease Patients Likely Includes Direct Enterocyte Effects That Exacerbate Disease. Clinical Gastroenterology and Hepatology, 2018, 16, 1679-1680.	4.4	1
29	Environmental Factors Modify the Severity of Acute DSS Colitis in Caspase-11-Deficient Mice. Inflammatory Bowel Diseases, 2018, 24, 2394-2403.	1.9	9
30	The Inhibitory Innate Immune Sensor NLRP12 Maintains a Threshold against Obesity by Regulating Gut Microbiota Homeostasis. Cell Host and Microbe, 2018, 24, 364-378.e6.	11.0	158
31	Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome. Digestive Diseases and Sciences, 2018, 63, 1890-1899.	2.3	72
32	Inflammation-independent TL1A-mediated intestinal fibrosis is dependent on the gut microbiome. Mucosal Immunology, 2018, 11, 1466-1476.	6.0	64
33	Act1 is a negative regulator in T and B cells via direct inhibition of STAT3. Nature Communications, 2018, 9, 2745.	12.8	33
34	Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nature Microbiology, 2018, 3, 234-242.	13.3	118
35	Intestinal bacterial biofilms modulate mucosal immune responses. , 2018, 2, 13-18.		5
36	Gut microbial composition can differentially regulate bile acid synthesis in humanized mice. Hepatology Communications, 2017, 1, 61-70.	4.3	35

#	Article	IF	CITATIONS
37	Dietary Salt Exacerbates Experimental Colitis. Journal of Immunology, 2017, 199, 1051-1059.	0.8	61
38	NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growth. Nature Immunology, 2017, 18, 541-551.	14.5	225
39	Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. Gastroenterology, 2017, 152, 327-339.e4.	1.3	615
40	Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology, 2016, 64, 1232-1248.	7.3	83
41	Alterations to chromatin in intestinal macrophages link ILâ€10 deficiency to inappropriate inflammatory responses. European Journal of Immunology, 2016, 46, 1912-1925.	2.9	30
42	Transient activation of mucosal effector immune responses by resident intestinal bacteria in normal hosts is regulated by interleukinâ€10 signalling. Immunology, 2016, 148, 304-314.	4.4	16
43	Lymphoid-Tissue-Resident Commensal Bacteria Promote Members of the IL-10 Cytokine Family to Establish Mutualism. Immunity, 2016, 44, 634-646.	14.3	126
44	Characterization of candidate genes in inflammatory bowel disease–associated risk loci. JCI Insight, 2016, 1, e87899.	5.0	30
45	Advances in understanding Giardia: determinants and mechanisms of chronic sequelae. F1000prime Reports, 2015, 7, 62.	5.9	104
46	Surface-Associated Lipoproteins Link Enterococcus faecalis Virulence to Colitogenic Activity in IL-10-Deficient Mice Independent of Their Expression Levels. PLoS Pathogens, 2015, 11, e1004911.	4.7	42
47	Resident Bacteria-Stimulated Interleukin-10-Secreting B Cells Ameliorate T-Cell-Mediated Colitis by Inducing T-Regulatory-1 Cells That Require Interleukin-27 Signaling. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 295-310.	4.5	36
48	Adherent-Invasive Escherichia coli Production of Cellulose Influences Iron-Induced Bacterial Aggregation, Phagocytosis, and Induction of Colitis. Infection and Immunity, 2015, 83, 4068-4080.	2.2	41
49	Infliximab Re-treatment in Inflammatory Bowel Disease: A Single-Center Routine Clinical Experience. Clinical Gastroenterology and Hepatology, 2015, 13, 1704-1705.	4.4	0
50	Small Heat-Shock Proteins, IbpAB, Protect Non-Pathogenic Escherichia coli from Killing by Macrophage-Derived Reactive Oxygen Species. PLoS ONE, 2015, 10, e0120249.	2.5	11
51	The Antipsychotic Olanzapine Interacts with the Gut Microbiome to Cause Weight Gain in Mouse. PLoS ONE, 2014, 9, e115225.	2.5	147
52	The Intestinal Microbiota in Inflammatory Bowel Diseases. Nestle Nutrition Institute Workshop Series, 2014, 79, 29-39.	0.1	33
53	Inflammation-associated Adherent-invasive Escherichia coli Are Enriched in Pathways for Use of Propanediol and Iron and M-cell Translocation. Inflammatory Bowel Diseases, 2014, 20, 1919-1932.	1.9	135
54	Innate PI3K p110δ Regulates Th1/Th17 Development and Microbiota-Dependent Colitis. Journal of Immunology, 2014, 192, 3958-3968.	0.8	53

4

#	Article	IF	CITATIONS
55	Molecular detection of bacterial contamination in gnotobiotic rodent units. Gut Microbes, 2013, 4, 361-370.	9.8	39
56	Induction of dsRNA-activated protein kinase links mitochondrial unfolded protein response to the pathogenesis of intestinal inflammation. Gut, 2012, 61, 1269-1278.	12.1	125
57	Diet promotes dysbiosis and colitis in susceptible hosts. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 561-562.	17.8	41
58	IL-10 Regulates <i>Il12b</i> Expression via Histone Deacetylation: Implications for Intestinal Macrophage Homeostasis. Journal of Immunology, 2012, 189, 1792-1799.	0.8	68
59	Altered Macrophage Function Contributes to Colitis in Mice Defective in the Phosphoinositide-3 Kinase Subunit p110l´. Gastroenterology, 2010, 139, 1642-1653.e6.	1.3	78
60	Microbial–Host Interactions in Inflammatory Bowel Diseases and Experimental Colitis. Nestle Nutrition Workshop Series Paediatric Programme, 2009, 64, 121-137.	1.5	23
61	Microbial Influences in Inflammatory Bowel Diseases. Gastroenterology, 2008, 134, 577-594.	1.3	1,683
62	Therapeutic correction of bacterial dysbiosis discovered by molecular techniques. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16413-16414.	7.1	80
63	Bacteria in Crohn's Disease. Journal of Clinical Gastroenterology, 2007, 41, S37-S43.	2.2	53
64	Microbial host interactions in IBD: Implications for pathogenesis and therapy. Current Gastroenterology Reports, 2007, 9, 497-507.	2.5	96
65	Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 390-407.	1.7	1,454
66	Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts. FASEB Journal, 2006, 20, A1465.	0.5	1
67	Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology, 2004, 126, 1620-1633.	1.3	952
68	Targeting enteric bacteria in treatment of inflammatory bowel diseases. Current Opinion in Gastroenterology, 2003, 19, 358-365.	2.3	79
69	Clinical applications of advances in the genetics of IBD. Reviews in Gastroenterological Disorders, 2003, 3 Suppl 1, S9-17.	0.6	4
70	Innate immunity in the pathogenesis and therapy of IBD. Journal of Gastroenterology, 2003, 38 Suppl 15, 43-7.	5.1	12
71	Low endogenous prostaglandin E2 predisposes to relapsing inflammation in experimental rat enterocolitis. Digestive Diseases and Sciences, 2000, 45, 2091-2099.	2.3	10
72	Inhibition of NF?B in activated rat hepatic stellate cells by proteasome inhibitors and an I?B super-repressor. Hepatology, 1998, 27, 1285-1295.	7.3	170

#	Article	IF	CITATIONS
73	Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats. FASEB Journal, 1998, 12, 325-333.	0.5	48
74	Enteric Microflora in IBD: Pathogens or Commensals?. Inflammatory Bowel Diseases, 1997, 3, 230-235.	1.9	38
75	Enteric microflora in IBD: Pathogens or commensals?. Inflammatory Bowel Diseases, 1997, 3, 230-235.	1.9	96
76	Enteric Microflora in IBD: Pathogens or Commensals?. Inflammatory Bowel Diseases, 1997, 3, 230-5.	1.9	28
77	Lessons in IBD Pathogenesis from New Animal Models of Spontaneous Colitis. Canadian Journal of Gastroenterology & Hepatology, 1995, 9, 309-315.	1.7	1